BRIDGEWATER, N.J., May 17, 2019 /PRNewswire/ — Salix Pharmaceuticals («Salix»), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced that it will launch the Salix Gastrointestinal Health Scholars Program, a new, annual scholarship program designed to provide financial support to outstanding students living with GI disease, as they pursue their higher education goals.

Salix Pharmaceuticals, Ltd. Logo (PRNewsfoto/Salix Pharmaceuticals, Ltd.)

The Salix Gastrointestinal Health Scholars Program will award 10 recipients, including students pursuing undergraduate or graduate degrees, up to $10,000 each. The commitment is part of a series of Salix-related announcements taking place at Digestive Disease Week® (DDW), the world’s largest meeting of GI healthcare professionals.

«The Salix Gastrointestinal Health Scholars is aimed at providing financial support to outstanding students who have not allowed GI disease to stand in the way of their academic achievements. We’re proud to support these high achievers as they continue their studies,» said Mark McKenna, president, Salix Pharmaceuticals.

Salix plans to open applications for the Salix Gastrointestinal Health Scholars Program in the fall of 2019 and fulfill its commitment of awarding 10 recipients starting in the spring of 2020. Winners will be announced annually by Salix at DDW beginning in 2020.

About Salix
Salix is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For 30 years, Salix has licensed, developed, and marketed innovative products to improve patients’ lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey.

Forward-looking Statements 
This news release may contain forward-looking statements, which may generally be identified by the use of the words «anticipates,» «expects,» «intends,» «plans,» «should,» «could,» «would,» «may,» «will,» «believes,» «estimates,» «potential,» «target,» or «continue» and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Bausch Health’s most recent annual or quarterly report and detailed from time to time in Bausch Health’s other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. Bausch Health believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health and Salix undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

© 2019 Salix Pharmaceuticals or its affiliates.
SAL.0079.USA.19

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/salix-pharmaceuticals-pledges-annual-100-000-scholarship-program-to-outstanding-students-living-with-gi-disease-300852411.html

SOURCE Salix Pharmaceuticals, Ltd.